Viridian Therapeutics (VRDN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Viridian Therapeutics

NasdaqCM•Healthcare•Biotechnology

$22.00+0.07(<0.01%)Market closed

Market Cap

$2.37B

P/S

33.4x

P/B

3.6x

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

How this company scores

WeakMetricSide Score: 39/100

Grade capped at D — Interest coverage below 1× (-12.2x) — earnings cannot cover interest. Strongest: Growth (16/25); weakest: Profitability (5/25).

Profitability5/25

Growth16/25

Balance Sheet & Red Flags12/25

Cash & Earnings Quality6/25

Strengths

Growing revenueLow leverageConsistent growthNet cash position

Grade capped at D

Interest coverage below 1× (-12.2x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 33.4x5y range 25.0x – 5003.5x

Currently below its 20-quarter median.

P/B · 3.6x5y range 0.9x – 3.6x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.37B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $71.13M
Q. Revenue: $284,000
TTM EBITDA: $-404.51M
TTM Op. Income: $-405.20M
Q. Op. Income: $-126.27M
TTM Net Income: $-386.97M
Q. Net Income: $-127.12M
EPS: $-1.05
Shares Out.: $107.88M

$71.13M in TTM revenue grew 23220.3% YoY, reaching $284,000 last quarter. TTM EBITDA of $-404.51M and TTM operating income of $-405.20M show growth is flowing through to the bottom line. However, net income is negative at $386.97M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 100.0%
EBITDA Margin: -44419.4%
Op. Margin: -44460.6%
Net Margin: -44760.2%

Op. margin of -44460.6% is up 97895.4% YoY — cost efficiency is improving. Net margin at -44760.2% and gross margin of 100.0% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 33.4x
P/B Ratio: 3.6x

P/S of 33.4x and P/B of 3.6x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.10B
Cash: $164.99M
Long-Term Debt: $113.64M
Book Value: $662.10M
D/E Ratio: 0.2
Debt/EBITDA: N/A

With $1.10B in assets and $113.64M in long-term debt, D/E is 0.2and book value is $662.10M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 4 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-105.32M
TTM Free Cash Flow: $-335.04M
FCF Margin: -471.0%
FCF / Net Income: 0.9

TTM FCF of $-335.04M on $-105.32M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.